adenine has been researched along with unc2025 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Cummings, CT; DeRyckere, D; Earp, HS; Frye, SV; Glaros, TG; Graham, DK; Hunter, D; Janzen, WP; Kireev, D; Lee, M; Liu, J; Minson, KA; Newton, DL; Sather, S; Stashko, MA; Wang, X; Zhang, D; Zhang, W | 1 |
| Cummings, CT; Davies, KD; DeRyckere, D; Earp, HS; Frye, SV; Graham, DK; Kirkpatrick, GD; Wang, X; Zhang, D; Zhang, W | 1 |
| DeRyckere, D; Dwivedi, B; Earp, HS; Frye, SV; Graham, DK; Keating, AK; Kowalski, J; Lee-Sherick, AB; Pierce, AM; Rupji, M; Sufit, A; Varella-Garcia, M; Wang, X | 1 |
| Bash, RE; Cohen, SM; Earp, HS; Ewend, MG; Frady, LN; Frye, SV; Gilbert, MR; Irvin, DM; Miller, CR; Schorzman, AN; Su, YT; Sulman, EP; Wang, X; Wu, J; Zamboni, WC | 1 |
| Acevedo, G; Branchford, BR; Brass, LF; Brzezinski, C; Davizon-Castillo, P; DeRyckere, D; Di Paola, JA; Frye, SV; Graham, DK; Law, L; Lee-Sherick, AB; Lentz, SR; Minson, K; Neeves, KB; Ng, C; Sather, S; Shelton Earp, H; Stalker, TJ; Wang, X; Wilson, KM; Zhang, W | 1 |
| Cosemans, JMEM | 1 |
| Bagby, SM; Burstyn-Cohen, T; Carrico, J; DeRyckere, D; Earp, HS; Eckhardt, SG; Frye, SV; Graham, DK; Kami, R; Minson, KA; Robinson, WA; Sinik, L; Tentler, JJ; Wang, X | 1 |
| Datta, A; Dorsey, A; Liu, B; Majumder, R; Pilli, VS | 1 |
| Basta, BN; Dew, KE; Friedman, RS; Jacobelli, J; Lindsay, RS; Rodriguez, E; Sandor, AM; Tracy, D; Whitesell, JC; Yannacone, SF | 1 |
9 other study(ies) available for adenine and unc2025
| Article | Year |
|---|---|
UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
Topics: Adenine; Administration, Oral; Animals; Biological Availability; c-Mer Tyrosine Kinase; Cell Line, Tumor; Chemistry Techniques, Synthetic; fms-Like Tyrosine Kinase 3; Humans; Inhibitory Concentration 50; Leukemia, B-Cell; Mice, SCID; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2014 |
Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; c-Mer Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Mice; Neoplastic Stem Cells; Oncogenes; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.
Topics: Adenine; Antineoplastic Agents; c-Mer Tyrosine Kinase; Cell Death; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Intercellular Signaling Peptides and Proteins; Neural Stem Cells; Piperazines; Polyploidy; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases | 2016 |
MerTK as a therapeutic target in glioblastoma.
Topics: Adenine; Animals; Brain Neoplasms; c-Mer Tyrosine Kinase; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Microglia; Piperazines; Receptor Protein-Tyrosine Kinases | 2018 |
The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.
Topics: Adenine; Animals; Axl Receptor Tyrosine Kinase; Blood Platelets; c-Mer Tyrosine Kinase; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Mice, Inbred C57BL; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pulmonary Embolism; Purinergic P2Y Receptor Antagonists; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thrombosis | 2018 |
At the MERcy of platelet primers.
Topics: Adenine; Blood Platelets; c-Mer Tyrosine Kinase; Humans; Piperazines; Platelet Activation; Thrombosis | 2018 |
Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Topics: Adenine; Animals; Azetidines; c-Mer Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; GTP Phosphohydrolases; Humans; Melanoma; Membrane Proteins; Mice; Mutation; Phosphorylation; Piperazines; Piperidines; Proto-Oncogene Proteins B-raf; Signal Transduction; Vemurafenib | 2019 |
Modulation of protein S and growth arrest specific 6 protein signaling inhibits pancreatic cancer cell survival and proliferation.
Topics: Adenine; Adenocarcinoma; Apoptosis; Axl Receptor Tyrosine Kinase; c-Mer Tyrosine Kinase; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Intercellular Signaling Peptides and Proteins; Piperazines; Protein S; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2020 |
MERTK on mononuclear phagocytes regulates T cell antigen recognition at autoimmune and tumor sites.
Topics: Adenine; Animals; Antigen-Presenting Cells; Antigens; Autoimmunity; c-Mer Tyrosine Kinase; CD11 Antigens; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Humans; Islets of Langerhans; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Transgenic; Neoplasms, Experimental; Phagocytes; Piperazines; T-Lymphocytes | 2021 |